Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.

BACKGROUND Testing of blood donors for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) RNA by means of nucleic acid amplification was introduced in the United States as an investigational screening test in mid-1999 to identify donations made during the window period before seroconversion. METHODS We analyzed all antibody-nonreactive donations that were confirmed to be positive for HIV-1 and HCV RNA on nucleic acid-amplification testing of "minipools" (pools of 16 to 24 donations) by the main blood-collection programs in the United States during the first three years of nucleic acid screening. RESULTS Among 37,164,054 units screened, 12 were confirmed to be positive for HIV-1 RNA--or 1 in 3.1 million donations--only 2 of which were detected by HIV-1 p24 antigen testing. For HCV, of 39,721,404 units screened, 170 were confirmed to be positive for HCV RNA, or 1 in 230,000 donations (or 1 in 270,000 on the basis of 139 donations confirmed to be positive for HCV RNA with the use of a more sensitive HCV-antibody test). The respective rates of positive HCV and HIV-1 nucleic acid-amplification tests were 3.3 and 4.1 times as high among first-time donors as among donors who gave blood repeatedly. Follow-up studies of 67 HCV RNA-positive donors demonstrated that seroconversion occurred a median of 35 days after the index donation, followed by a low rate of resolution of viremia; three cases of long-term immunologically silent HCV infection were documented. CONCLUSIONS Minipool nucleic acid-amplification testing has helped prevent the transmission of approximately 5 HIV-1 infections and 56 HCV infections annually and has reduced the residual risk of transfusion-transmitted HIV-1 and HCV to approximately 1 in 2 million blood units.

[1]  N. D. Kalmin,et al.  First report of human immunodeficiency virus transmission via an RNA‐screened blood donation , 2004, Vox sanguinis.

[2]  M. Busch,et al.  NAT and blood safety: what is the paradigm? , 2000, Transfusion.

[3]  S. Kleinman,et al.  The Risk of Transfusion-Transmitted Viral Infections , 1996 .

[4]  David Wright,et al.  HIV seroconverting donors delay their return: screening test implications , 2002, Transfusion.

[5]  S. Stramer,et al.  NAT of the United States and Canadian blood supply , 2000, Transfusion.

[6]  J. AuBuchon,et al.  The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations , 2003, Transfusion.

[7]  U. Desselberger,et al.  Hepatitis C virus infections in transplant patients: Serological and virological investigations , 1994, Journal of medical virology.

[8]  J. Bartlett.  Transmission of west nile virus through blood transfusion in the United States in 2002 , 2004 .

[9]  M. Goldman.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes , 1999 .

[10]  S. Stramer,et al.  Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population , 2002, Transfusion.

[11]  S. Kleinman,et al.  Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood‐donor screening , 2003, Transfusion.

[12]  S. Stramer,et al.  Prolonged antibody‐negative HCV viremia in a US blood donor with apparent HCV transmission to a recipient , 2000, Transfusion.

[13]  T. Wright,et al.  Acute hepatitis C , 2001, Hepatology.

[14]  M. Busch.  Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. , 2001, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[15]  P. Holland,et al.  Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays , 2002, Transfusion.

[16]  J. Goudsmit,et al.  Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. , 1999, Blood.

[17]  S. Kleinman,et al.  Current and emerging infectious risks of blood transfusions. , 2003, JAMA.

[18]  L. Mimms,et al.  Highly Sensitive Multiplex Assay for Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA , 2002, Journal of Clinical Microbiology.

[19]  M. Busch,et al.  The Efficiency of HIV p24 Antigen Screening of US Blood Donors: Projections versus Reality , 1998, Transfusion Medicine and Hemotherapy.

[20]  M. Alter,et al.  Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[21]  J. Stapleton,et al.  Surreptitious hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. , 1997, The Journal of infectious diseases.

[22]  R. Dodd.  Emerging infections, transfusion safety, and epidemiology. , 2003, The New England journal of medicine.

[23]  M. Busch,et al.  History of posttransfusion hepatitis. , 1997, Clinical chemistry.

[24]  M. Alter,et al.  Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti‐HCV , 2004, Transfusion.

[25]  A. Williams,et al.  Seroprevalence of known and putative hepatitis markers inUnited States blood donors with ALT levels at least 120 IU per L , 2001, Transfusion.

[26]  J. Wong,et al.  Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States , 2004, Vox sanguinis.

[27]  M. Busch,et al.  Nucleic acid amplification technology methods used in blood donor screening , 2002, Transfusion medicine.

[28]  Michael P Busch,et al.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection , 2003, AIDS.

[29]  E. Lehmann.  Testing Statistical Hypotheses , 1960 .

[30]  S. Kleinman,et al.  Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. , 2000, Transfusion.

[31]  M. Chamberland,et al.  Emerging infectious agents: do they pose a risk to the safety of transfused blood and blood products? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.